- Home
- DDD vs TNGX Comparison
DDD vs TNGX Comparison
Compare DDD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDD
- TNGX
- Stock Information
- Founded
- DDD 1986
- TNGX 2014
- Country
- DDD United States
- TNGX United States
- Employees
- DDD N/A
- TNGX N/A
- Industry
- DDD Computer peripheral equipment
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DDD Technology
- TNGX Health Care
- Exchange
- DDD Nasdaq
- TNGX Nasdaq
- Market Cap
- DDD 386.0M
- TNGX 413.6M
- IPO Year
- DDD N/A
- TNGX N/A
- Fundamental
- Price
- DDD $3.51
- TNGX $3.10
- Analyst Decision
- DDD Buy
- TNGX Strong Buy
- Analyst Count
- DDD 3
- TNGX 8
- Target Price
- DDD $3.00
- TNGX $13.14
- AVG Volume (30 Days)
- DDD 3.8M
- TNGX 1.5M
- Earning Date
- DDD 11-26-2024
- TNGX 11-06-2024
- Dividend Yield
- DDD N/A
- TNGX N/A
- EPS Growth
- DDD N/A
- TNGX N/A
- EPS
- DDD N/A
- TNGX N/A
- Revenue
- DDD $443,945,000.00
- TNGX $43,383,000.00
- Revenue This Year
- DDD N/A
- TNGX $27.73
- Revenue Next Year
- DDD $3.28
- TNGX N/A
- P/E Ratio
- DDD N/A
- TNGX N/A
- Revenue Growth
- DDD N/A
- TNGX 15.67
- 52 Week Low
- DDD $1.72
- TNGX $2.70
- 52 Week High
- DDD $6.85
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- DDD 54.02
- TNGX 39.37
- Support Level
- DDD $3.48
- TNGX $2.72
- Resistance Level
- DDD $4.04
- TNGX $3.29
- Average True Range (ATR)
- DDD 0.34
- TNGX 0.30
- MACD
- DDD 0.03
- TNGX 0.05
- Stochastic Oscillator
- DDD 55.35
- TNGX 31.25
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on-demand manufacturing services, and digital design tools. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.